SS Innovations (NASDAQ: SSII) doubles 2025 revenue and lifts margins
Rhea-AI Filing Summary
SS Innovations International, Inc. furnished a June 2026 investor presentation highlighting rapid growth in its surgical robotics business. Revenue rose to $42.5M in 2025 from $20.6M in 2024, while gross margin expanded to 46.0% from 40.9%, and net loss narrowed to $8.16M from $19.15M.
The SSi Mantra robotic system has performed 11,270 multi-specialty surgeries with 210 systems installed across 186 hospitals as of May 31, 2026, with no significant safety events reported. For the quarter ended March 31, 2026, revenue was $11.1M, more than double the prior-year quarter, and gross margin reached 48.0%.
The company held $23.6M in cash and no long-term debt as of March 31, 2026, and reported insider ownership of roughly 74% of its 200.1 million shares outstanding as of June 2, 2026. The presentation also outlines ongoing global expansion, with regulatory approvals in India and multiple countries and anticipated EU CE marking in Q4 2026 and a 510(k) pathway toward potential FDA market clearance around Q4 2026–Q1 2027.
Positive
- Rapid revenue growth and margin expansion: Revenue grew to $42.5M in 2025 with a stated +169% CAGR since 2023, while gross margin rose from 12.3% in 2023 to 46.0% in 2025, indicating improving economics.
- Narrowing losses with solid balance sheet: Net loss declined from $19.15M in 2024 to $8.16M in 2025, and as of March 31, 2026 the company held $23.61M in cash and no long-term debt.
- Strong adoption and safety record: By May 31, 2026, 210 SSi Mantra systems supported 11,270 surgeries across 186 hospitals, with zero significant safety events reported, underscoring clinical traction.
- Visible global expansion path: The company lists regulatory approvals in multiple countries, with EU CE marking targeted for Q4 2026 and a U.S. FDA 510(k) review underway aiming for market clearance around Q4 2026–Q1 2027.
Negative
- Business still operating at a loss: Despite growth, SS Innovations reported an operating loss of $8.19M and net loss of $8.16M in 2025, and a net loss of $3.58M for the quarter ended March 31, 2026.
- Revenue concentration in India: The company states that approximately 87% of 2025 revenue came from India, indicating reliance on a single foundational market while international revenue is still developing.
Insights
SS Innovations shows triple-digit revenue growth, margin expansion and growing robotics adoption while still operating at a loss.
SS Innovations reports strong scaling in its surgical robotics platform. Revenue increased from $5.9M in 2023 to $42.5M in 2025, with stated growth rates of +251% and a +169% revenue CAGR from 2023 to 2025. Gross margin improved from 12.3% in 2023 to 46.0% in 2025, indicating better pricing, mix or cost structure.
The company remains loss-making, but operating loss shrank from $20.27M in 2023 to $8.19M in 2025, and diluted EPS improved from $(0.14) to $(0.06). As of March 31, 2026, cash of $23.61M and zero long-term debt provide financial flexibility, though sustainability depends on continued growth and margin trends.
Commercial adoption metrics are notable: cumulative SSi Mantra installations rose from 18 in 2023 to 168 in 2025 and 210 by May 31, 2026, supporting 11,270 surgeries with no significant safety events reported. Future results will hinge on executing the global expansion and achieving the anticipated EU CE marking in Q4 2026 and potential FDA 510(k) clearance around Q4 2026–Q1 2027.
8-K Event Classification
Key Figures
Key Terms
Regulation FD Disclosure regulatory
forward-looking statements regulatory
gross margin financial
diluted EPS financial
510(k) regulatory
CE Marking regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 7.01 Regulation FD Disclosure.
June 2026 Company Presentation
Included with this Current Report as Exhibit 99.1 is an updated January 2026 Company Presentation (the “Company Presentation”), which SSi intends to use in communications to shareholders and the investment community.
Regulation FD Disclosure
The information set forth in Items 7.01 of this Current Report and in the Company Presentation included as Exhibit 99.1 to this Current Report, are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report and in the Company Presentation included as Exhibit 99.1 to this Current Report, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
This Current Report and the Company Presentation included as Exhibit 99.1 to this Current Report that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations and other statement that are predictive in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | June 2026 Company Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Furnished not filed |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 15, 2026 | SS INNOVATIONS INTERNATIONAL, INC. | |
| By: | /s/ Sudhir Srivastava | |
| Sudhir Srivastava, M.D. | ||
| Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
We Build Advanced, Affordable and Accessible Surgical Robotic Solutions SS Innovations International, Inc. Company Presentation June 2026 Nasdaq: SSII
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 2 No Offering of Securities No offer is made by this Company Presentation (this "Presentation") to invest in SS Innovations International, Inc. (the "Company") or to purchase any of its securities. Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company. Forward-Looking Statements This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward-looking statements. Examples of forward-looking statements include statements regarding the benefits, uses and safety of our products, projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services. In some cases, you can identify forward-looking statements by the use of terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. Actual events or results may differ materially. We undertake no obligation to update any of the forward-looking statements after the date of this Presentation to conform them to actual results. Please refer to the risk factors described in the "Risk Factors" section and other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC. Statistical and Other Industry and Market Data This Presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, and management is responsible for the accuracy of such assumptions and data, no independent source has verified such assumptions. Disclaimers
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 3 Our Vision To continuously improve and deploy our technologically- advanced, cost-effective surgical robotic systems, while maintaining affordability and accessibility for the benefit of a larger segment of patients globally
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 4 Snapshot of SS Innovations • We develop innovative, differentiated surgical robotic technologies, highlighted by our: • Proprietary surgical robotic system, the SSi Mantra 3; • Comprehensive suite of surgical instruments, which support a variety of surgical procedures, including robotic cardiac surgery; • AI- and XR-driven imaging, training and simulation platform; and • Pioneering telesurgery capabilities. • We are backed by a team of leading surgical robotics experts and seasoned medical technology executives. • We are a rapidly growing American company with Indian roots, expanding globally and preparing for our strategic entry into Europe and the United States. • Including the Company's strong foundational market of India, the SSi Mantra installed base currently spans 12 countries. 11,270 Multi-Specialty Surgeries 210 SSI Mantra Systems Installed 186 Hospitals 174 Validated Surgical Procedures 9 Surgical Specialities 587 Robotic Cardiac Surgeries 171 Telesurgeries 0 # of Significant Safety Events Reported Note: Data as of May 31, 2026 2022 Year of Commercialization
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 5 Snapshot of SS Innovations (Continued) Headquarters Gurugram, India Company Domicile Florida, USA Employees (May 11, 2026) 523 Year Merged with Avra Medical 2023 Year Uplisted to Nasdaq 2025 Ticker SSII Exchange Nasdaq-CM Shares Out (June 2, 2026) 200.1 mm Recent Price (June 2, 2026) $4.01 Market Cap (June 2, 2026) $0.8 bn Insider Ownership (June 2, 2026) ~74% 4,869 2,686 1,969 631 587 287 125 105 11 General Surgery Urology Gynecology Colorectal Cardiac Gastrointestinal Head & Neck Thoracic Breast and Plastic 11,270 Total Surgeries to Date1 1. Data as of May 31, 2026; 173 of these procedures were pediatric surgeries 78 194 As of 3/31/25 As of 3/31/26 Systems Installed (cumulative data) 5.9 20.6 42.5 5.1 11.1 2023 2024 2025 Q1'25 Q1'26 Revenue ($ millions) +149% +169% CAGR +106%
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 6 • Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology • Large and Growing Total Addressable Market with Favorable Industry Tailwinds • Advanced, Cost-Efficient Surgical Robotics Platform – Clinically and Commercially Differentiated • Established Presence in India with Global Expansion Underway • Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins • Strategy to Deliver Long-Term, Sustainable Growth 1 2 3 4 5 Investment Highlights 6
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 7 Sudhir Srivastava, MD, Founder, Chairman & CEO • Robotic cardiac surgeon with 40+ years of experience • Pioneered many of the world's first robotic cardiac procedures • Performed numerous robotic cardiac surgeries and trained surgical teams worldwide • University of British Columbia, University of Chicago, Alliance Hospital • Owns 114,468,548 shares, or 58.8% of SSII shares outstanding1 Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology 1. As of 5/20/2026 Frederic Moll, MD, Vice-Chairman • Former Chief Development Officer, J&J Medical Devices • Founder, Intuitive Surgical, Hansen Medical, Auris Health • Co-Founder & Partner, Sonder Capital Management • Board Member, PROCEPT BioRobotics, Neptune Medical, Moon Surgical • Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT • Owns 20,836,298 shares, or 10.4% of SSII shares outstanding1 Vishwajyoti Srivastava, MD, Chief Executive Officer, APAC & Board Member • Led the development of the OMNI 3D Medical Visualization system • Serves as the President of OMNI 3D HD to advance existing technological platform for availability in the global surgical and endoscopic marketplace • Previously served as the VP of Marketing and Technology at the International Centre for Robotic Surgery in New Delhi • Columbia University, Saint James School of Medicine Barry Cohen, COO – Americas & Board Member • Co-Founder, CEO and Director, Avra Medical Robotics • Former Director and President, Synalloy Corp. • Former Chairman of the Board, Wolverine Technologies Dr. Mylswamy Annadurai, Board Member • Former Director, Indian Space Research Organization Somashekhar SP, MD, Board Member • Robotic Surgeon • Global Director, Aster International Institute of Oncology Tim Paul Adams, Board Member • Regional Operating Officer, Ascension • Former Regional CEO, Tenet Healthcare • Chairman, Tennessee Hospital Association
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 8 Demographics Disease Burden Workforce Challenges Economics Patient Benefits Surgeon Benefits Improved resource utilization, increased revenue, reduced cost with lower complication rates and shorter lengths of stay SSII aims to accelerate access to surgical robotics in underserved regions of the world Key Market Trends Technology Innovation and enhanced capabilities make next-generation systems versatile across a broad spectrum of surgeries Aging global population driving increased need for surgical interventions Growing incidence of chronic and lifestyle diseases Helps address increasing shortage of trained healthcare workers, by reducing labor intensity across each care episode Improved economics for providers and payers Reduced patient trauma, shorter recovery times, and enhanced patient outcomes Ergonomic systems reduce staff fatigue and enhanced training pathways across varying skill levels improves adoption Hospital Benefits Large and Growing Addressable Market with Favorable Industry Tailwinds Accelerated Global Adoption of Robotic Surgery 12.0 13.7 27.1 2024 2025 2030 Global Surgical Robotics Market (in USD billions)1 +14.7% CAGR 1. Sourced from December 2025 Markets and Markets Surgical Robots Market Report
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 9 Benefits of Robotic Surgery In the 20 Years Since Launch of Robotic Surgery, Access Remains Limited Key Challenges of Existing Systems High cost of acquisition and implementation Unattractive economics for hospitals with lower volumes Absence of trained personnel Lack of versatility and adaptability of systems and limited systems with multi- specialty capabilities Greater Precision Minimal Blood Loss Faster Recovery 10x Magnified 3D vision Less Pain and Discomfort Reduced Surgeon Fatigue Smaller Incisions on Patients Reduced Risk of Infection Large and Growing Addressable Market with Favorable Industry Tailwinds Access to Robotic Surgery Remains Limited Installed base largely limited to the US, EU and Japan Only 5% of installed systems are "available" to ~7 billion people outside the US, EU and Japan Less than 1% of surgical procedures worldwide each year are performed robotically1 1. Estimate sourced from secondary market research
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 10 ~70,000 Hospitals 1.5 Hospital Beds per 1,000 people (compared to the recommended 3)¹ Estimated need of 5,000 surgeries per year per 100,000 people2 ~1.4 Billion Population 1944 Surgical Robotic Systems are SSi Mantra 11,2704 Robot Assisted Surgeries performed in India on the SSi Mantra Estimated 2,100+4 Robotic Surgeons trained on the SSi Mantra 1. Sourced from 2020 BIS Global Surgical Robotics Market Report 2. Sourced from 2023 Lancet Regional Health Southeast Asia 3. Sourced from Intuitive Surgical: 'About India'. Accessed January 2026 4. Data as of May 31, 2026 5. Sourced from December 2025 Markets and Markets Surgical Robots Market Report 6. Sourced from Intuitive Surgical: 'Statement on daVinci X.' Accessed January 2026 950 robotic-assisted trained surgeons and >180 da Vinci robotic-assisted surgical systems installed across major private and government hospitals3 >100,000 da Vinci procedures performed⁶ Global surgical robotics market is expected to reach $27.1 billion USD by 2030⁵ Large and Growing Addressable Market with Favorable Industry Tailwinds Unmet Needs and Market Opportunity Support Our Foundational Market in India
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 11 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 1 2 3 1 Surgical Command Center Ergonomic open-faced console comprised of a pair of passive 3D glasses, a 3D 4k resolution monitor and a 2D touch monitor for system controls 2 Patient-Side Robotic Arm Carts Modular robotic arms mounted on individual carts with the option of using 3, 4 or 5 robotic arm configurations 3 Vision Cart 3D 4K resolution monitor, identical to the surgeon's console, for OR staff. Also houses the control system for the articulating endoscope and camera and pre- operative guidance software 4 Instrument and Accessories Comprehensive suite of stapling, energy and core instrumentation for the surgical system under the brand name SSi Mudra 4
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 12 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 – Surgical Command Center Ergonomic Open-Faced Console Large 3D 4K Monitor Large 2D Touch Monitor for System Controls and DICOM access Lightweight Magnetic Hand Controls Design Head Tracking Safety Feature Digital Ergonomics Control Tele Surgery and Tele Proctoring Enabled
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 13 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 – Patient Side Robotic Arm Carts Modular Robotic Carts Freedom of Patient Docking 3/4/5 Patient Cart Connectivity Absolute Stability Parking Locks Smaller Individual Cart Footprint Advanced Touch Screen Controls
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 14 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mudra – Multi Specialty Robotic Instruments 7 Degrees of Freedom Articulating Robotic Instruments 10 Use Life Cycle per Instrument 20+ Cardiac Specialty Instruments Only company in the world actively advocating for robotic cardiac surgery Untapped market potential in automated coronary artery bypass surgery 400+ complex robotic cardiac surgeries performed with the SSi Mantra 40+ Types of Instruments Novel Instrument: Automated Coronary Anastomotic Connector1 Novel Instrument: Multi-Fire Clip Applier2 Advanced Instruments: Selicut Harmonic Advanced Instruments: ExpertSeal Vessel Sealer Advanced Instruments: Anastoflex Stapler 1. Includes instruments under development. 2. Under development. 1 1 On January 6, 2026, the Company announced the development of five new 5- millimeter surgical robotic instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 15 Advanced, Cost-Efficient Surgical Robotics Platform SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies SSi Guru XR Tele Proctoring System • Mixed Reality Headset • Portable 3D Surgery Viewer • Interactive Virtual Screens • CDSCO Approved • Virtual Tele Illustration Feature • Proctored over 1,200 miles under 400 ms latency AR Smart Glasses1 3D Visualization System • 3D HD 1080p vision • Variable IPD adjustments • Direct from endoscope video signal processing • IMU based head tracking Cognitive Skill Simulator1 A different approach to train surgeons • Overlaid instruments tracking • Guided procedure steps • Trains cognition and muscle memory • Enhancing motor skills through repetition • Console and VR based learning system Mixed reality-powered and AI-enabled technologies for better training, visualization, and simulation for the entire surgical team. 1. In development
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 16 Advanced, Cost-Efficient Surgical Robotics Platform Pioneering Telesurgery Capabilities and Mobile Robotic Telesurgery Unit First system approved for telesurgery in India.1 We enhance remote surgical access and empower underserved communities through telesurgery, surgical education, mentoring, and real-time data insights. 1. CDSCO approval (India) 2. As of 5/31/26 3. Communication line distance SSII HQ Gurugram, India Aster CMI Hospital Bengaluru, India 1,245 miles Mar 2025 IRCAD HQ Strasbourg, France Sri Aurobindo IMS Indore, India 4,000+ miles Jul 2025 Perth, Australia Sri Aurobindo IMS Indore, India 6,250+ miles3 Apr 2025 171 telesurgeries have been completed with the SSi Mantra surgical robotic system2 March 2026 - SSi Mantra approved for telesurgery in Indonesia and the Philippines Georgetown, Guyana IRCAD Indore, India 12,500+ miles3 May 2026 World's Longest-Distance Robotic Telesurgery
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 17 Advanced, Cost-Efficient Surgical Robotics Platform The SSi MantrAsana Tele-Surgeon Console Facilitates Telesurgery from "Anywhere" Compact Self- Contained Chair Inbuilt Electronics Magnetic Sensor- Based Controls Lightweight Glasses Magnified Three- Dimensional View SSi MantrAsana Tele-Surgeon Console Enables Portability Requires Less Space Facilitates Telesurgery from Physician's Offices and other Locations with Limited Working Space
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 18 Established Presence in India with Global Expansion Underway World-Class R&D and Manufacturing Facilities to Support Growth and Cost Efficiency R&D, Manufacturing, Assembly, and Operations in Gurgaon, Delhi National Capital Region (India) Proximity to New Delhi International airport with excellent connectivity with all parts of the world ~91,000 sq ft space spread over three floors as of May 31, 2026 20 Systems per month Current Production Capacity Manpower of 523 as of May 11, 2026 Plan to expand manufacturing to match growth 91,000 sq ft FACILITY
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 19 78 194 As of 3/31/25 As of 3/31/26 Cumulative Installed Base 3,568 9,744 As of 3/31/25 As of 3/31/26 Completed Procedures Installed base Overview of Installed Base +149% +173% Academic center Established Presence in India with Global Expansion Underway SSi Mantra 3 Is Demonstrating Rapid Adoption Across Various Geographies 210 as of May 31, 2026 11,270 as of May 31, 2026
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 20 EU CE Anticipated Q4 '26 Guyana 2026 US FDA Anticipated Q4 '26 / Q1 '27 Established Presence in India with Global Expansion Underway Global Expansion - Regulatory Approvals India CDSCO 2023 Colombia 2025 Indonesia 2024 Guatemala 2023 In 2025, SS Innovations generated approximately 87% of its revenue from India. We expect the percentage of total revenue coming from the rest of the world to significantly expand over time. Oman 2025 Kenya 2026 Australia, Brunei, Laos, Morrocco, Thailand, Vietnam Anticipated 2026 Philippines 2025 Ukraine 2025 Iraq 2025 UAE 2025 Ecuador 2024 Sri Lanka 2026 Nepal 2026 Chile, Nigeria, Mauritius Approval Not Required
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 21 Route of conformity to Notified body Certification EN ISO 13485 Completed Stage 1 Audit Desktop Q4 2025 Technical File Review Q2 2026 CE Marking Q4 2026 2 Initial Review- Application and Technical File March 2025 Notified body – SZUTEST, Germany Current Stage Stage 2 Audit On Site Q1 2026 EU CE Mark 1. Human factor validation in the US 2. Dependent on the outcome of the review process Established Presence in India with Global Expansion Underway Estimated Regulatory Timelines FDA Q Sub Regulatory Strategy Feedback, Biocompatibility, Reprocessing 2024 510(k) Technical dossier preparation1 510(k) Submitted for Multi-Specialty Indications Q4 2025 FDA Review / Market Clearance Q4 2026 / Q1 2027 2 Current Stage US FDA File Under Review Q2 2026
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 22 85% 15% $42.5 mm Revenue 2025 Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins $5.9 $20.6 $42.5 2023 2024 2025 Revenue ($ millions) +251% Gross Margin (%) 12.35% 40.93% 46.00% 2023 2024 2025 +2,858 bps +507 bps Revenue Mix (%) Systems Capital Sales Recurring 1 +106% 1. Recurring revenue defined as systems on rental / lease, instruments and consumables sales and maintenance service fees
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 23 15 26 Q1'25 Q1'26 SSi Mantra Installations (# of systems) First Quarter 2026 – Robust Growth in Revenue and SSi Mantra Installations and Procedures $5.1 $11.1 Q1'25 Q1'26 Revenue ($ millions) +117% +73% 787 1,859 Q1'25 Q1'26 SSi Mantra Procedures (# of surgeries) +136%
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 24 Growth Strategy Continuously Improve and Innovate Our Top-Tier Robotics Platform through New Product Development and Enhanced Technology. Maintain Stronghold in India, Grow in Select Underserved Countries with Low Penetration and Cost Barriers, and Pursue Established Markets. In the United States, after FDA approval Focus on ASCs and Smaller Hospitals while Leveraging the SSi Mantra's Differentiated Cardiac Surgery Capabilities. Focus on Large Multi-Specialty Hospitals • Secure Initial Placements • Expand # of Physicians using Mantra 3 • Increase System Utilization at Each Hospital • Place Additional Systems at Each Hospital (Go Deeper) Target Leading Surgeons and Thought Leaders to Raise Awareness and Encourage Widespread Adoption • Indian Medical Advisory Board • International Advisory Board • Medical Conferences • Robotic Surgery Training Programs • Strategic Partners (e.g., Johns Hopkins) Platform Value • Advanced Technology • Lower Cost • Ease of Training • Improved Patient Outcomes • Differentiated Features (e.g., Cardiac)
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 25 Appendix
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 26 FY 2023 – FY 2025 Financial Summary SS Innovations Twelve Months Ended Three Months Ended Statement of Operations (in USD) Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2025 March 31, 2025 March 31, 2026 Revenue 5,875,314 20,649,528 42,484,747 5,120,610 11,101,366 Gross Profit 725,528 8,452,366 19,544,255 1,087,208 5,327,221 Gross margin 12.3% 40.9% 46.0% 21.2% 48.0% Operating (loss) income (20,273,984) (18,975,962) (8,194,034) (5,921,853) (3,638,757) Net (loss) income (20,878,292) (19,151,197) (8,160,947) (5,681,353) (3,582,571) Diluted EPS $(0.14) $(0.11) $(0.06) $(0.03) $(0.02) Diluted shares 152,069,825 181,203,673 198,699,461 188,599,859 205,309,556 Balance Sheet (in USD) March 31, 2026 Cash1 23,611,050 Current assets 66,261,517 Total assets 90,546,889 Current liabilities 26,045,003 Long term debt - Total stockholders' equity 54,523,413 1. Includes restricted cash of $7,631,336
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 27 Summary of SSi Mantra Installations 3 15 47 103 2022 2023 2024 2025 3 18 65 168 2022 2023 2024 2025 Year # Growth 2022 3 - 2023 15 400% 2024 47 213% 2025 103 119% Year # Growth 2022 3 - 2023 18 500% 2024 65 261% 2025 168 158% Annual Installations Cumulative Installations1 1At end of period Year # Growth Q1'24 9 - Q2'24 10 - Q3'24 6 - Q4'24 22 - Q1'25 15 67% Q2'25 23 130% Q3'25 27 350% Q4'25 38 73% Q1'26 26 73% Quarterly Installations 9 10 6 22 15 23 27 38 26 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Note: all growth % figures are year over year comparisons
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 28 www.ssinnovations.com investors@ssinnovations.org Investor Contact: Kalle Ahl, CFA (303) 953-9878 kahl@theequitygroup.com